As GCS is the target, or is downstream in the lipid biosynthesis pathway of aberrant signaling in patients with ADPKD, the GCS inhibitor venglustat may have the potential to attenuate GSL production and slow cyst formation (Fig 1). Here, UGCG is linked to cyst.